1029Infection-Related Hospital Readmissions Following Prostate Biopsy in United States Men

Content Provider	Semantic Scholar
Author	Evans, Richard Loeb, Aram Cher, Michael L. Kaye, Keith S. Martin, Emily Toth
Copyright Year	2014
Abstract	Background. Common antibiotic prophylactic strategies for prostate biopsy may be insufficient to prevent procedure-associated sepsis, particularly with the rise of Gram-negative pathogens that are resistant to fluoroquinolones. We aim to describe all-cause and infection-related readmission rates and costs in a national sample of men undergoing prostate biopsy. Methods. We compared mean rates of readmission within 30 days of prostate biopsy from January 2005 to December 2011. Insurance claims data was obtained from the Marketscan Commercial Claims and Encounters database. Yearly rates of prostate biopsy and readmissions were calculated from the number of inpatient admissions and outpatient services (including emergency room visits) in men of at least 40 years of age with a documented CPT-4 code of 55700 for prostate biopsy. Patients were required to be continuously enrolled in at least one insurance program for at least 30 days after prostate biopsy for inclusion in the analysis. Results. 447,486 men with a prostate biopsy were eligible for inclusion. Mean age of the population was 62.8 years of age (SD 8.9). 13,154 of these patients (2.9%) were readmitted within 30 days of biopsy. Median length of stay during readmission was 3 days (IQR: 2) and mean total payment for the hospitalization was $14,749.09 (SD $22,767.11). The most common major diagnostic category upon readmission was reproductive diseases (4786 readmissions) followed by infectious diseases (2539 readmissions; 0.6% of all prostate biopsies). Conclusion. Despite widespread use of antibiotic prophylaxis for prevention of infection following prostate biopsy, infection remains the second most common reason for 30-day hospital readmission, possibly due in part, to the emergence of multidrug resistant pathogens. Continued efforts are needed to optimize prophylaxis strategies. Disclosures. All authors: No reported disclosures.
Starting Page	S301
Ending Page	S302
Page Count	2
File Format	PDF HTM / HTML
PubMed reference number	5782114
Volume Number	1
Language	English
Access Restriction	Open
Subject Keyword	Accident and Emergency department Antibiotic Prophylaxis Antibiotics Biopsy Communicable Diseases Condoms, Unspecified Current Procedural Terminology (Version 4) Disclosure Document completion status - Documented Emergence Endocrine System Diseases Fluoroquinolones Hospital admission Hospitalization Medical ultrasound Patients Physiological Sexual Disorders Prostatic Neoplasms Sepsis ambulatory care services gram
Content Type	Text
Resource Type	Article